People: AstraZeneca PLC (AZN.L)
19 Dec 2013
Dr. Bahija Jallal is the Executive Vice President, MedImmune of AstraZeneca PLC., since January 2013 and is responsible for biologics research, development and clinical activities. Bahija is tasked with advancing the biologic pipeline of drugs. Bahija joined MedImmune as Vice-President, Translational Sciences in 2006 and has held roles of increasing responsibility. Prior to joining AstraZeneca, Bahija worked with Chiron Corporation where she served as Vice-President, Drug Assessment and Development. Bahija received a master’s degree in biology from the Université de Paris VII and her doctorate in physiology from the Université Pierre et Marie Curie, Paris. She conducted her postdoctoral research at the Max-Planck Institute of Biochemistry in Martinsried, Germany. She is a member of the American Association of Cancer Research, the American Association of Science, the Pharmacogenomics Working Group and is a member of the Board of Directors of the Association of Women in Science.
|Total Annual Compensation,||Long-Term Incentive Plans,||All Other,||Fiscal Year Total,|